SCHEMBL10249340

SCHEMBL10249340

Cc1cnc2c(c1)nc(-c1ccncc1OCc1ccccc1)n2C

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 2/20 0.41
IKBKB O14920 3/20 0.41
BUB1 O43683 1/20 0.41
STAT3 P40763 1/20 0.40
HTT P42858 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
PDE10A Q9Y233 2/20 0.40
PDE2A O00408 1/20 0.40
GCK P35557 1/20 0.39
CYP1A2 P05177 2/20 0.39
CYP19A1 P11511 2/20 0.38
CYP11B1 P15538 2/20 0.38
CYP11B2 P19099 2/20 0.38
ALDH1A1 P00352 1/20 0.38
TSHR P16473 1/20 0.38
CLK4 Q9HAZ1 1/20 0.38
RHEB Q15382 1/20 0.38
LRRK2 Q5S007 1/20 0.37
AKT1 P31749 1/20 0.37
AKT2 P31751 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL116559 0.87 GPBAR1 (0.42) IKBKBBUB1STAT3HTTSMN1; SMN2
SCHEMBL10249089 0.85 POLB (0.40) SMN1; SMN2PDE10AAKT1AKT2
SCHEMBL10248867 0.85 SMN1; SMN2 (0.44) IKBKBBUB1STAT3HTTSMN1; SMN2
SCHEMBL10248934 0.83 PDE1A (0.39) BRD4BUB1SMN1; SMN2PDE10APDE2A
SCHEMBL10249083 0.83 POLB (0.50) SMN1; SMN2PDE10APDE2AAKT1AKT2
SCHEMBL10249154 0.82 POLB (0.38) BRD4SMN1; SMN2PDE10AAKT1AKT2
SCHEMBL10249232 0.82 BUB1 (0.39) BRD4BUB1SMN1; SMN2PDE10AAKT1
SCHEMBL10249085 0.82 MELK (0.41) BRD4SMN1; SMN2PDE10AAKT1AKT2
SCHEMBL10249027 0.82 MAPT (0.43) BRD4SMN1; SMN2PDE10AAKT1AKT2
SCHEMBL10249030 0.82 POLB (0.40) BUB1SMN1; SMN2PDE10APDE2AAKT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8461181-B2 Fused heterocyclic compound and use thereof SUMITOMO CHEMICAL COMPANY, LTD. (JP) 2013-06-11 US disclosed
US-8273764-B2 Fused heterocyclic compounds and use thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-09-25 US disclosed
US-20120178779-A1 FUSED HETEROCYCLIC COMPOUND AND USE THEREOF SUMITOMO CHEMICAL COMPANY, LIMITED 2012-07-12 US disclosed
US-20120015975-A1 FUSED HETEROCYCLIC COMPOUND AND USE THEREOF SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-01-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120178779-A1 FUSED HETEROCYCLIC COMPOUND AND USE THEREOF C3AR1, C9, C5 BRD4 513/4885IKBKB 3387/4885BUB1 2962/4885
US-20120015975-A1 FUSED HETEROCYCLIC COMPOUND AND USE THEREOF C3AR1, C9, C5 BRD4 513/4885IKBKB 3387/4885BUB1 2962/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.